Drug
BI 3000202 Low Dose
BI 3000202 Low Dose: highest development phase Phase 1, developed by Boehringer Ingelheim. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| BI 3000202_low dose NCT06878365 | Phase 1 | Type 1 Interferonopathies |
Latest
No recent events.
Follow BI 3000202 Low Dose on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.